ALZ-801 | CAT# 1034190-08-3 | prodrug of tramiprosate

MedKoo Cat#: 563784 | Name: ALZ-801

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation for Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved pharmacokinetic properties and gastrointestinal tolerability.

Chemical Structure

ALZ-801

CAS#1034190-08-3

Theoretical Analysis

MedKoo Cat#: 563784

Name: ALZ-801

CAS#: 1034190-08-3

Chemical Formula: C8H18N2O4S

Exact Mass: 238.0987

Molecular Weight: 238.30

Elemental Analysis: C, 40.32; H, 7.61; N, 11.76; O, 26.85; S, 13.45

Price and Availability

Size	Price	Availability
5mg	USD 106.00	Ready to ship
10mg	USD 190.00	Ready to ship
25mg	USD 420.00	Ready to ship
50mg	USD 750.00	Ready to ship
100mg	USD 1,375.00	Ready to ship
200mg	USD 1,950.00	Ready to ship
500mg	USD 2,950.00	Ready to ship
1g	USD 4,350.00	2 Weeks
2g	USD 7,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

3687-18-1

Synonym

ALZ-801; ALZ801; ALZ 801; BLU8499; BLU 8499; BLU-8499; NRM8499; NRM 8499; NRM-8499

IUPAC/Chemical Name

(S)-3-(2-Amino-3-methylbutanamido)propane-1-sulfonic acid

InChi Key

NRZRFNYKMSAZBI-ZETCQYMHSA-N

InChi Code

InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1

SMILES Code

O=S(CCCNC([C@@H](N)C(C)C)=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Certificate of Analysis

View CoA: current batch, Lot# A21T03K23

QC Data

View QC data: current batch, Lot# A21T03K23

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Water	250.0	1,049.10

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 238.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w. PMID: 32787971; PMCID: PMC7424995. 2: Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020 Nov;16(11):1553-1560. doi: 10.1016/j.jalz.2019.09.075. Epub 2020 Jan 3. PMID: 31706733. 3: Tolar M, Hey J, Power A, Abushakra S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355. PMID: 34198582; PMCID: PMC8231952. 4: Hey JA, Yu JY, Versavel M, Abushakra S, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. doi: 10.1007/s40262-017-0608-3. PMID: 29063518; PMCID: PMC5814546. 5: Cao Y, Yu F, Lyu Y, Lu X. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Front Neurol. 2022 Nov 15;13:1034243. doi: 10.3389/fneur.2022.1034243. PMID: 36457865; PMCID: PMC9706102. 6: Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M. Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018 Dec;32(12):1185. doi: 10.1007/s40263-018-0585-6. Erratum for: CNS Drugs. 2018 Sep;32(9):849-861. PMID: 30421245; PMCID: PMC6828218. 7: Hey JA, Kocis P, Hort J, Abushakra S, Power A, Vyhnálek M, Yu JY, Tolar M. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018 Sep;32(9):849-861. doi: 10.1007/s40263-018-0554-0. Erratum in: CNS Drugs. 2018 Dec;32(12):1185. PMID: 30076539; PMCID: PMC6153967. 8: Prebble DW, Er S, Hlushchuk I, Domanskyi A, Airavaara M, Ekins MG, Mellick GD, Carroll AR. α-Synuclein binding activity of the plant growth promoter asterubine. Bioorg Med Chem Lett. 2022 May 15;64:128677. doi: 10.1016/j.bmcl.2022.128677. Epub 2022 Mar 14. PMID: 35301136. 9: Abushakra S, Porsteinsson AP, Sabbagh M, Bracoud L, Schaerer J, Power A, Hey JA, Scott D, Suhy J, Tolar M; Alzheimer's Disease Neuroimaging Initiative. APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimers Dement (N Y). 2020 Dec 4;6(1):e12117. doi: 10.1002/trc2.12117. PMID: 33304988; PMCID: PMC7716452. 10: Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis. 2017;4(3):149-156. doi: 10.14283/jpad.2017.26. PMID: 29182706. 11: Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z. PMID: 28435985; PMCID: PMC5488121.